- $1.43bn
- $1.47bn
- $1.30m
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
NASDAQ RESUMED AT 08:00 AM
Brief: Inhibrx's Inbrx-106 Nearly Doubles Response Rate And Achieves Interim Median Pfs Of 9.6 Months In Phase 2 Hnscc Study
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
Inhibrx falls on wider-than-expected quarterly loss
Inhibrx Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Inhibrx Biosciences Q2 net loss widens on higher expenses
Inhibrx Q1 net loss narrows as R&D costs fall
Brief: Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy
Brief: Inhibrx to host webcast presentation to provide clinical update on INBRX-106 HexAgon study in first line HNSCC
Merck, rivals eye Inhibrx experimental cancer drug tied to Keytruda, sources say
U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway
U.S. STOCKS ON THE MOVE-Certara, Otis, Twilio
U.S. STOCKS ON THE MOVE-Best Buy, Teleflex, Philip Morris
NASDAQ RESUMED AT 09:38 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
Inhibrx rises as experimental drug tied to Merck’s Keytruda catches drugmakers' eye
Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say